France: The French Act N°2011-2012 Dated 29 December 2011 Relating To The Reinforcement Of Health Security Of Medicinal And Health Products

This Act is focused on three main objectives:

  • Combating conflicts of interest and promoting transparency
  • Strengthening the monitoring of medicinal products and medical devices
  • Making better information more readily available to patients and healthcare professionals and, in particular, establishing binding provisions covering the advertisement of drugs, medical and diagnostics devices

This Act appears to be the French version of "Sunshine Acts" found in other countries. The Act also creates a new national agency, the Agence Nationale de Sécurité des Médicaments (ANSM), replacing the AFSSAPS in August of 2012. The ANSM will have new roles and powers, such as the power to impose administrative and financial penalties. Numerous provisions of this Act are still subject to follow-up decrees by the ANSM.

The main features of this new Act are the following:


  • Obligation to Declare Positions of Interest
    The Act expands the list of persons holding regulatory powers devolved to them by the French Ministry of Health, cabinet members and members of the new ANSM subject to the obligation to declare their interests when they take office: experts and all other professionals holding a regulatory role (New Article L.1451-1 of the French Public Health Code).
  • Administrative and Financial Penalties: Annulment of the decisions taken by these persons / Fines of up to 30,000 Euros. (New Article L.1454-2 of the French Public Health Code)
  • Obligation to Disclose Compensation
    The Act imposes an obligation to publicly disclose any agreement for providing direct or indirect compensation1 to a number of persons expressly listed (e.g. health professionals, organisations of health professionals, students and students associations of students in healthcare related studies, organisations of consumers of the health industry, health establishments, foundations, consulting organisations involved healthcare business, communication and publishing businesses involved in the life sciences market, software companies providing software concerning the drafting and delivery of medical prescriptions, companies involved in the education of healthcare professionals). (New Article L.1453-1 of the French Public Health Code)

    • Business Subject to the New Act: Business which manufacture, distribute and market cosmetics or medicinal products intended for humans, or which provide services linked with these products.
    • Financial Penalties Under the New Act: Up to 45,000 Euros fines for individuals and up to 225,000 Euros for companies, without affecting other possible additional penalties and sentences. (New Articles L.1454-3 seq. of the French Public Health Code)


  • The Act creates a new agency named Agence Nationale de Sécurité des Médicaments et produits de santé (ANSM) replacing the AFSSAPS (New Articles L.5311-1 seq. of the French Public Health Code)

    • The ANSM will determine the risks and benefits linked to the use of health products intended for humans as well as cosmetics, monitoring the benefit/risk ratio of products and to act as an authoritative body with the power to impose fines and injunctions depending on the seriousness of the breach or violation.
    • The ANSM will publish all communications, notices, minutes and reports of commissions, committees and expert meetings within this agency (except in cases of industrial, commercial and professional confidentiality)

  • The Act also reinforces the obligations of pharmacovigilance in the medical industry with respect to the follow-up of their products after marketing authorisation (AMM)
    (The ANSM must be informed without delay of any imposed prohibition or restriction of any suspension of marketing of the authorisation-holder in France) – (New Articles L. 5121-9-2 seq. of the French Public Health Code)


  • A public web site with information on medications is to be set up.
  • Information campaigns on medication including its characteristics, risks and its proper use are to be conducted.
  • Continuing education obligations are imposed on all healthcare practitioners.
  • New provisions concerning the advertising of medicinal products

    • For medicinal products intended for humans

      • Advertising medicinal products is prohibited when the product is subject to a re-appraisal of its benefit/risk ratio following a reporting of pharmacoviligance (new Article L.5122-3 of the French Public Health Code)
      • Advertising campaigns concerning medicinal products intended to prevent smoking, reduce the addiction to smoking, or for vaccinations which are subject to medical prescription or reimbursed by French social security.
      • Advertising intended to healthcare professionals is subject to the mandatory prior authorisation of the ANSM. Such authorisation is referred to as « visa de publicité » (advertising visa) (new Article L.5122.9 of the French Public Health Code). Advertisements which have been published before the enactment of this reform shall remain subject to the old regime for one year following the date of this enactment (30 December 2011).

        • Amending the French Intellectual Property Code that now provides that documents needed for the granting of the visa de publicité shall not amount to counterfeiting.
      • Two year experimentation of a new system according to which medical representative shall only be able to make presentation and visits in healthcare establishments before a group of healthcare professionals (i.e. not on an individual basis).
    • Concerning medical devices: New Articles L.5211-3 seq. and L 5223-1 of the French Public Health Code

      • Control of advertising in relation to medical devices and harmonizing this regime to the regime applicable to medicinal products
      • Public advertising of reimbursed medical devices by the French NHS/Medicare is prohibited, except for devices which present a low risk to public health (list to be determined by decree).
      • Mandatory prior authorisation of the ANSM for medical devices presenting an important health risk (list to be determined by decree).

        • Penalties: a maximum of two years of imprisonment and a fine of up to 30,000 Euros in the following cases:

          • Where an advertisement is of a deceptive nature or presents a public health risk.
          • Where an advertisement is broadcasted or communicated without having obtained the visa de publicite, or if this authorisation was terminated or refused.

Other penalties are also provided for both individuals and legal entities.


The Act includes an important provision allowing a generic drug to copy the appearance or the texture of an original medicinal product in its oral shape (New Article L.5121-10-3 of the French Public Health Code).

* * * * * * * * * *

This Act will lead to noticeable changes for pharmaceutical and cosmetics companies (concerning transparency requirements) in France in the management of their internal procedures and their compliance requirements.


1. The threshold of which will be determined by decree.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.